Photo from ESTRO/X
Jul 25, 2024, 08:21
5-year results of the hypo-FLAME trial on focal boost SBRT for prostate cancer – ESTRO
European Society for Radiotherapy and Oncology (ESTRO) shared a post on X:
“5-year results of the hypo-FLAME trial on focal boost SBRT for intermediate/high-risk prostate cancer. Presented at ESTRO24, it shows excellent biochemical disease-free survival (93%) and low toxicity with a 5-fraction SBRT schedule.”
Read further.
Source: ESTRO/X